August 18, 2023 at 6:35 PM EDT Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer injections First and only treatment [...]
August 10, 2023 at 7:00 AM EDT TWO-YEAR PULSAR TRIAL RESULTS FOR AFLIBERCEPT 8 MG DEMONSTRATE DURABLE VISION GAINS AT EXTENDED DOSING INTERVALS IN WET AGE-RELATED MACULAR DEGENERATION 88% of all aflibercept 8 mg patients were on a ≥12-week dosing [...]
WALTHAM, Mass., July 30, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from the GALE extension study following 30 months of continuous treatment with SYFOVRE® (pegcetacoplan injection), the first and only FDA approved treatment for geographic atrophy [...]
February 23, 2023 at 7:00 AM EST AFLIBERCEPT 8 MG BLA FOR TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION AND DIABETIC MACULAR EDEMA ACCEPTED FOR FDA PRIORITY REVIEW BLA supported by two pivotal trials demonstrating non-inferior vision gains to EYLEA® (aflibercept) Injection, [...]
The Support Sight Foundation and founder Dawn Prall were so excited to be featured on the podcast Healthcare on the Horizon. In this podcast, Dawn talks about the prevalence of macular degeneration. Take a listen below! Hi everyone. [...]
WALTHAM, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company has submitted a New Drug Application (NDA) to the United States Food and Drug [...]
Modus Outcomes, a scientific research company, will be doing a global survey later this year for the MOSAIC study. The study explores people’s experiences with geographic atrophy (GA), which is also known as advanced dryage-related macular degeneration (AMD). We are [...]
"Research makes medicine" guides our mission to find a cure! We continue to fund groundbreaking research that was started many years ago by the Macula Vision Research Foundation (MVRF). Our mission to save sight for millions with MacD – is [...]
Dawn Prall and Joshua Dunaief discuss AMD Central, a new site for people living with the condition Recently, I talked to Dawn Prall, founder and executive director of The SupportSight Foundation, and Joshua L. Dunaief, Adele Niessen Professor of Ophthalmology [...]
The STEP Program™: Supporting Solutions From Patient Advocacy Organizations Patient advocacy organizations are a key source of information, empowerment, and support for patients at every step of their health care experience, helping them and their families navigate the care they need. [...]
The Support Sight Foundation is a 501(c)(3) public charity EIN# 83-1475951.The official registration and financial information may be obtained from the PA Department of State PA ID# 115901. Call 800-732-0999. Registration does not imply endorsement. All contributions are tax-deductible to the full extent of the law.
IRS regulations require us to inform you that no goods or services were provided in return for your gift. TSSF is a 501(c)(3) tax exempt organization.
We would be happy to provide you with a current audited financial report upon request. Please allow 1- 7 business days for a response.
Please contact us:
By Mail: 45 E. City Ave # 516, Bala Cynwyd, PA 19004-2621
By Phone: 888-681-8773 or 610-952-3034
By Email: info@supportsight.org
Copyright ©2023 Support Sight Foundation | All Rights Reserved
